title: Extended field radiation and cisplatin for stage IIB and IIIB cervical carcinoma.
abstract: OBJECTIVE
  The aim of this study was to investigate local regional control, survival, and morbidity in patients with FIGO IIB and IIIB squamous cell carcinoma of the cervix treated with primary extended field (prophylactic paraaoratic radiation) radiation and weekly cisplatin.
  
  
  METHODS
  Sixty-seven patients (44 IIB and 23 IIIB) with carcinoma of the cervix received cisplatin at 1 mg/kg (up to 60 mg) weekly and extended field radiation therapy including the paraaortic nodes and brachytherapy.
  
  
  RESULTS
  After the scheduled therapy 94.1% of the patients were complete responders. Seventy-five percent are alive without evidence of disease with a mean follow-up of 47.5 months.
  
  
  CONCLUSIONS
  This study confirms the ability to give concomitant weekly cisplatin and prophylactic paraaortic radiation with minimal morbidity. The encouraging Kaplan-Meier survival of 75% and only eight pelvic failures warrants further investigation.
authors.affiliation: Division of Gynecologic Oncology, Albany Medical Center, Albany, New York 12208, USA.
authors.forename: J H
authors.initials: JH
authors.lastname: Malfetano
authors.forename: H
authors.initials: H
authors.lastname: Keys
authors.forename: M J
authors.initials: MJ
authors.lastname: Cunningham
authors.forename: S
authors.initials: S
authors.lastname: Gibbons
authors.forename: R
authors.initials: R
authors.lastname: Ambros
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001918:Brachytherapy; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin